Zeskind Benjamin J. 4
4 · Immuneering Corp · Filed Jun 24, 2026
Research Summary
AI-generated summary of this filing
Immuneering (IMRX) CEO Benjamin Zeskind Buys 2,400 Shares
What Happened
Benjamin J. Zeskind, President, CEO and Director of Immuneering Corp (IMRX), made an open-market purchase of 2,400 shares on June 23, 2026. The weighted average purchase price reported was $4.56 per share, for a total cash outlay of approximately $10,948. The filing lists the transaction code P (purchase) and the shares were acquired for the benefit of the Benjamin J. Zeskind 2020 Family Trust.
Key Details
- Transaction date: 2026-06-23 (Period of Report); Form 4 filed 2026-06-24 (timely filing).
- Price: weighted average $4.56/share; executed in multiple trades at prices ranging $4.55–$4.59 (footnote F1).
- Shares purchased: 2,400; total value ≈ $10,948.
- Shares owned after transaction: not specified in the filing.
- Beneficial ownership/holding vehicle: held by the Benjamin J. Zeskind 2020 Family Trust; Lisa Schwartz (spouse) is sole trustee (footnote F2).
- Transaction code: P = Purchase. No 10b5-1 plan, tax withholding, or option exercise noted.
Context
This was a direct insider purchase (not an award or option exercise) and is commonly viewed by investors as a more informative signal than routine sales, though it does not guarantee future performance. The filing is timely and discloses the trade was executed across multiple trades — the registrant offers to provide per-trade details to the SEC upon request.
Insider Transaction Report
- Purchase
Class A Common Stock
[F1]2026-06-23$4.56/sh+2,400$10,948→ 2,315,252 total
- 894,927(indirect: See Foonote)
Class A Common Stock
[F2]
Footnotes (2)
- [F1]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.55 to $4.59. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.
- [F2]Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.